Illustration: Eniola Odetunde/Axios
Thermo Fisher Scientific agreed to acquire clinical trial data company Clario Holdings from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven for $8.88 billion.
Why it matters: The acquisition is the second mega pharma deal this week, as biotech transactions, and dealmaking in general, make a comeback.
